Deep learning analysis of clinical course of primary nephrotic syndrome: Japan Nephrotic Syndrome Cohort Study (JNSCS).

Clinical course Creatinine Hematuria Machine learning Nephrotic syndrome Prognosis Proteinuria

Journal

Clinical and experimental nephrology
ISSN: 1437-7799
Titre abrégé: Clin Exp Nephrol
Pays: Japan
ID NLM: 9709923

Informations de publication

Date de publication:
Dec 2022
Historique:
received: 24 03 2022
accepted: 16 07 2022
pubmed: 13 8 2022
medline: 19 11 2022
entrez: 12 8 2022
Statut: ppublish

Résumé

Prognosis of nephrotic syndrome has been evaluated based on pathological diagnosis, whereas its clinical course is monitored using objective items and the treatment strategy is largely the same. We examined whether the entire natural history of nephrotic syndrome could be evaluated using objective common clinical items. Machine learning clustering was performed on 205 cases from the Japan Nephrotic Syndrome Cohort Study, whose clinical parameters, serum creatinine, serum albumin, dipstick hematuria, and proteinuria were traceable after kidney biopsy at 5 measured points up to 2 years. The clinical patterns of time-series data were learned using long short-term memory (LSTM)-encoder-decoder architecture, an unsupervised machine learning classifier. Clinical clusters were defined as Gaussian mixture distributions in a two-dimensional scatter plot based on the highest log-likelihood. Time-series data of nephrotic syndrome were classified into four clusters. Patients in the fourth cluster showed the increase in serum creatinine in the later part of the follow-up period. Patients in both the third and fourth clusters were initially high in both hematuria and proteinuria, whereas a lack of decline in the urinary protein level preceded the worsening of kidney function in fourth cluster. The original diseases of fourth cluster included all the disease studied in this cohort. Four kinds of clinical courses were identified in nephrotic syndrome. This classified clinical course may help objectively grasp the actual condition or treatment resistance of individual patients with nephrotic syndrome.

Sections du résumé

BACKGROUND BACKGROUND
Prognosis of nephrotic syndrome has been evaluated based on pathological diagnosis, whereas its clinical course is monitored using objective items and the treatment strategy is largely the same. We examined whether the entire natural history of nephrotic syndrome could be evaluated using objective common clinical items.
METHODS METHODS
Machine learning clustering was performed on 205 cases from the Japan Nephrotic Syndrome Cohort Study, whose clinical parameters, serum creatinine, serum albumin, dipstick hematuria, and proteinuria were traceable after kidney biopsy at 5 measured points up to 2 years. The clinical patterns of time-series data were learned using long short-term memory (LSTM)-encoder-decoder architecture, an unsupervised machine learning classifier. Clinical clusters were defined as Gaussian mixture distributions in a two-dimensional scatter plot based on the highest log-likelihood.
RESULTS RESULTS
Time-series data of nephrotic syndrome were classified into four clusters. Patients in the fourth cluster showed the increase in serum creatinine in the later part of the follow-up period. Patients in both the third and fourth clusters were initially high in both hematuria and proteinuria, whereas a lack of decline in the urinary protein level preceded the worsening of kidney function in fourth cluster. The original diseases of fourth cluster included all the disease studied in this cohort.
CONCLUSIONS CONCLUSIONS
Four kinds of clinical courses were identified in nephrotic syndrome. This classified clinical course may help objectively grasp the actual condition or treatment resistance of individual patients with nephrotic syndrome.

Identifiants

pubmed: 35962244
doi: 10.1007/s10157-022-02256-3
pii: 10.1007/s10157-022-02256-3
pmc: PMC9668942
doi:

Substances chimiques

Creatinine AYI8EX34EU

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1170-1179

Subventions

Organisme : Ministry of Health, Labour and Welfare
ID : 2031693

Informations de copyright

© 2022. The Author(s).

Références

Cell. 2019 Apr 4;177(2):463-477.e15
pubmed: 30951672
Clin Exp Nephrol. 2012 Dec;16(6):903-20
pubmed: 23053590
Lupus. 2014 Oct;23(11):1124-32
pubmed: 24860121
J Thromb Haemost. 2014 Sep;12(9):1449-54
pubmed: 25040558
Am J Kidney Dis. 2004 Feb;43(2):368-82
pubmed: 14750104
Am J Med. 2014 Sep;127(9):871-7.e1
pubmed: 24838191
Sci Rep. 2016 May 18;6:26137
pubmed: 27188851
Kidney Int. 1993 Sep;44(3):638-42
pubmed: 8231039
Sci Rep. 2019 Mar 25;9(1):5104
pubmed: 30911057
Clin Exp Nephrol. 2018 Feb;22(1):55-60
pubmed: 28478493
Clin Exp Nephrol. 2016 Jun;20(3):342-70
pubmed: 27099136
Cochrane Database Syst Rev. 2012 Apr 18;(4):CD003964
pubmed: 22513919
Kidney Blood Press Res. 2017;42(6):1045-1052
pubmed: 29197864
Nephrol Dial Transplant. 2011 Feb;26(2):414-30
pubmed: 21068142
Kidney Int. 2004 Apr;65(4):1400-7
pubmed: 15086481
Nat Rev Nephrol. 2018 Jan;14(1):57-70
pubmed: 29176657
Clin Exp Nephrol. 2011 Aug;15(4):493-503
pubmed: 21437579
Clin Exp Nephrol. 2021 Aug;25(8):893-901
pubmed: 33768329
Sci Data. 2019 Jun 17;6(1):96
pubmed: 31209213
Clin Exp Nephrol. 2018 Dec;22(6):1266-1280
pubmed: 29679356

Auteurs

Tomonori Kimura (T)

Reverse Translational Research Project, Center for Rare Disease Research, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki, Osaka, Japan. t-kimura@nibiohn.go.jp.
Laboratory of Rare Disease Resource Library, Center for Rare Disease Research, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki, Osaka, Japan. t-kimura@nibiohn.go.jp.

Ryohei Yamamoto (R)

Health and Counseling Center, Osaka University, Suita, Osaka, Japan.

Mitsuaki Yoshino (M)

Reverse Translational Research Project, Center for Rare Disease Research, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki, Osaka, Japan.

Ryuichi Sakate (R)

Reverse Translational Research Project, Center for Rare Disease Research, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki, Osaka, Japan.

Enyu Imai (E)

Nakayamadera Imai Clinic, Takarazuka, Hyogo, Japan.

Shoichi Maruyama (S)

Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.

Hitoshi Yokoyama (H)

Department of Nephrology, Kanazawa Medical University School of Medicine, Kanazawa, Japan.

Hitoshi Sugiyama (H)

Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Kosaku Nitta (K)

Department of Nephrology, Tokyo Women's Medical University, Tokyo, Japan.

Tatsuo Tsukamoto (T)

Department of Nephrology and Dialysis, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan.

Shunya Uchida (S)

Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.

Asami Takeda (A)

Kidney Disease Center, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Aichi, Japan.

Toshinobu Sato (T)

Department of Nephrology, JCHO Sendai Hospital, Sendai, Miyagi, Japan.

Takashi Wada (T)

Department of Nephrology and Laboratory Medicine, Kanazawa University, Kanazawa, Japan.

Hiroki Hayashi (H)

Department of Nephrology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.

Yasuhiro Akai (Y)

First Department of Internal Medicine, Nara Medical University, Nara, Japan.

Megumu Fukunaga (M)

Division of Nephrology, Department of Internal Medicine, Toyonaka Municipal Hospital, Toyonaka, Osaka, Japan.

Kazuhiko Tsuruya (K)

Department of Nephrology, Nara Medical University, Kashihara, Nara, Japan.

Kosuke Masutani (K)

Division of Nephrology and Rheumatology, Department of Internal Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.

Tsuneo Konta (T)

Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan.

Tatsuya Shoji (T)

Department of Kidney Disease and Hypertension, Osaka General Medical Center, Osaka, Japan.

Takeyuki Hiramatsu (T)

Department of Nephrology, Konan Kosei Hospital, Konan, Aichi, Japan.

Shunsuke Goto (S)

Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.

Hirofumi Tamai (H)

Department of Nephrology, Anjo Kosei hospital, Anjo, Aichi, Japan.

Saori Nishio (S)

Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

Kojiro Nagai (K)

Department of Nephrology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.

Kunihiro Yamagata (K)

Department of Nephrology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaragi, Japan.

Hideo Yasuda (H)

Internal Medicine 1, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.

Shizunori Ichida (S)

Department of Nephrology, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Aichi, Japan.

Tomohiko Naruse (T)

Department of Nephrology, Kasugai Municipal Hospital, Kasugai, Aichi, Japan.

Tomoya Nishino (T)

Department of Nephrology, Nagasaki University Hospital, Nagasaki, Japan.

Hiroshi Sobajima (H)

Department of Diabetology and Nephrology, Ogaki Municipal Hospital, Ogaki, Ogagki, Japan.

Toshiyuki Akahori (T)

Department of Nephrology, Chutoen General Medical Center, Kakegawa, Shizuoka, Japan.

Takafumi Ito (T)

Division of Nephrology, Shimane University Hospital, Izumo, Shimane, Japan.

Yoshio Terada (Y)

Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University, Kochi, Japan.

Ritsuko Katafuchi (R)

Kideny Unit, National Hospital Organization, Fukuoka-Higashi Medical Center, Koga, Fukuoka, Japan.

Shouichi Fujimoto (S)

Department of Hemovascular Medicine and Artificial Organs, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Hirokazu Okada (H)

Department of Nephrology, Saitama Medical University, Iruma, Saitama, Japan.

Tetsushi Mimura (T)

Department of Nephrology, Gifu Prefectural Tajimi Hospital, Tajimi, Gifu, Japan.

Satoshi Suzuki (S)

Department of Nephrology, Kainan Hospital, Yatomi, Aichi, Japan.

Yosuke Saka (Y)

Department of Nephrology, Yokkaichi Municipal Hospital, Yokkaichi, Mie, Japan.

Tadashi Sofue (T)

Department of Cardiorenal and Cerebrovascular Medicine, Kagawa University, Takamatsu, Kagawa, Japan.

Kiyoki Kitagawa (K)

Division of Internal Medicine, National Hospital Organization Kanazawa Medical Center, Kahoku, Kanazawa, Japan.

Yoshiro Fujita (Y)

Department of Nephrology, Chubu Rosai Hospital, Nagoya, Aichi, Japan.

Makoto Mizutani (M)

Department of Nephrology, Handa City Hospital, Handa, Aichi, Japan.

Naoki Kashihara (N)

Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan.

Hiroshi Sato (H)

Department of Nephrology, Endocrinology, and Vascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.

Ichiei Narita (I)

Division of Clinical Nephrology and Rheumatology, Kidney Research Center, School of Medical and Dental Sciences, Niigata University Graduate, Niigata, Japan.

Yoshitaka Isaka (Y)

Department of Nephrology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH